
Biopharma company Almirall and MC2 Therapeutics, a pharmaceutical company focused on therapies for autoimmune and chronic inflammatory conditions, have announced …

Eli Lilly’s tirzepatide led to significant haemoglobin A1C (HbA1C) and body weight reductions from baseline in adults with type 2 …

The past week has continued to see positive COVID-19 vaccine news; a WHO panel approved the Oxford-AstraZeneca vaccine for all …

Johnson & Johnson has applied to the EMA for marketing authorisation of their one-shot COVID-19 vaccine in Europe.

The OlympiA Phase III trial for AstraZeneca and MSD’s cancer drug Lynparza will move to early primary analysis and reporting, …

Novartis has entered into a grant agreement with the Bill & Melinda Gates Foundation, under which the foundation will fund …

The FDA has approved Novartis’ Entresto (sacubitril/valsartan) to reduce the risk of cardiovascular death and hospitalisation for heart failure in …

North Korea has tried to hack into Pfizer’s servers in order to ascertain its COVID-19 vaccine technology, according to a …

South Korea has arranged deals with Novavax and Pfizer-BioNTech to buy enough COVID-19 vaccines for 23 million more people.

The WHO has greenlighted two versions of the Oxford-AstraZeneca COVID-19 vaccine for emergency use, granting them authorisation to be rolled …

Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has been granted conditional authorisation in the UK as a monotherapy for the …

The European Commission (EC) has granted marketing authorisation for Celltrion’s Yuflyma, an adalimumab biosimilar, across all thirteen intended indications for …

The University of Glasgow and Eli Lilly and Company have entered into a research collaboration, across four diseases, worth £4.6 …

The Pfizer-BioNTech COVID-19 vaccine has been proven to be 94% effective, according to the first major study to evaluate the …

The Oxford-AstraZeneca COVID-19 vaccine is to be tested on children in the UK in a new trial commencing this month. …

Genentech has announced detailed, positive results from four Phase III studies of its investigational bispecific antibody, faricimab, for the treatment …

Molecular Templates and Bristol Myers Squibb have entered into a worldwide strategic research collaboration worth up to $1.3 billion, to …

Over the past week, AstraZeneca’s COVID-19 jab has been at the centre of disputes about vaccine efficiency both in older …

NICE has issued final draft guidance recommending the routine use of Bristol Myers Squibb (BMS)’s Opdivo (nivolumab) as an option …